MJP Associates Inc. ADV Has $254,000 Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

MJP Associates Inc. ADV raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 16.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 506 shares of the company’s stock after purchasing an additional 73 shares during the quarter. MJP Associates Inc. ADV’s holdings in IDEXX Laboratories were worth $254,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Avalon Trust Co bought a new position in IDEXX Laboratories in the first quarter worth $25,000. Ridgewood Investments LLC acquired a new position in shares of IDEXX Laboratories in the 1st quarter valued at $28,000. Altshuler Shaham Ltd acquired a new stake in shares of IDEXX Laboratories during the 4th quarter valued at about $26,000. Raleigh Capital Management Inc. bought a new stake in IDEXX Laboratories in the first quarter valued at about $33,000. Finally, Pacifica Partners Inc. acquired a new position in IDEXX Laboratories in the first quarter worth about $33,000. Institutional investors and hedge funds own 86.85% of the company’s stock.

IDEXX Laboratories Trading Up 0.3 %

Shares of NASDAQ:IDXX traded up $1.14 during midday trading on Monday, hitting $451.83. The company had a trading volume of 71,426 shares, compared to its average volume of 450,624. The firm has a fifty day simple moving average of $510.75 and a 200 day simple moving average of $490.76. The stock has a market cap of $37.50 billion, a price-to-earnings ratio of 47.92, a PEG ratio of 2.68 and a beta of 1.20. The company has a current ratio of 1.33, a quick ratio of 0.89 and a debt-to-equity ratio of 0.64. IDEXX Laboratories, Inc. has a 12 month low of $317.06 and a 12 month high of $564.73.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, August 1st. The company reported $2.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.43 by $0.24. The company had revenue of $943.63 million during the quarter, compared to analyst estimates of $927.84 million. IDEXX Laboratories had a net margin of 22.52% and a return on equity of 104.84%. On average, analysts predict that IDEXX Laboratories, Inc. will post 9.82 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on IDXX. Atlantic Securities lowered IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $610.00 price objective on the stock. in a research note on Wednesday, August 2nd. JPMorgan Chase & Co. increased their price objective on IDEXX Laboratories from $550.00 to $600.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 2nd. StockNews.com began coverage on shares of IDEXX Laboratories in a report on Thursday, August 17th. They issued a “buy” rating on the stock. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $525.00 to $500.00 and set a “hold” rating on the stock in a research report on Friday. Finally, Morgan Stanley raised their price objective on shares of IDEXX Laboratories from $590.00 to $600.00 and gave the stock an “overweight” rating in a report on Thursday, August 3rd. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $571.67.

Insider Activity

In related news, EVP James F. Polewaczyk sold 22,909 shares of the company’s stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $510.56, for a total value of $11,696,419.04. Following the completion of the transaction, the executive vice president now directly owns 10,038 shares of the company’s stock, valued at approximately $5,125,001.28. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CEO Jonathan Jay Mazelsky sold 13,424 shares of the stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $512.01, for a total transaction of $6,873,222.24. Following the completion of the transaction, the chief executive officer now owns 72,925 shares in the company, valued at $37,338,329.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP James F. Polewaczyk sold 22,909 shares of IDEXX Laboratories stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $510.56, for a total transaction of $11,696,419.04. Following the completion of the sale, the executive vice president now owns 10,038 shares in the company, valued at $5,125,001.28. The disclosure for this sale can be found here. Insiders have sold 52,360 shares of company stock worth $26,743,411 in the last 90 days. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.